Deutsche Bank’s Altamira Therapeutics Ltd CYTO Stock Holding History

Deutsche Bank’s Portfolio CYTO Stock Details CYTO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-16	Closed	-$5K	–	4519
2020 Q1	$5K	Hold	16	–	–	﹤0.01%	4154
2019 Q4	$10K	Buy	+16	New	+$10.8K	﹤0.01%	4501
2019 Q2	–	Sell	-4	Closed	-$10K	–	5581
2019 Q1	$10K	Buy	+4	New	+$12.9K	﹤0.01%	4930
2016 Q3	–	Hold	0	–	–	–	5275
2016 Q2	–	Hold	0	–	–	–	5395
2016 Q1	–	Hold	0	–	–	–	5390
2015 Q4	–	Hold	0	–	–	–	5092
2015 Q3	–	Hold	0	–	–	–	5392
2015 Q2	–	Hold	0	–	–	–	5508
2015 Q1	–	Hold	0	–	-$43K	–	6126
2014 Q4	–	Hold	0	–	–	–	5203
2014 Q3	–	Hold	0	–	–	–	5286

Other funds holding CYTO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Deutsche Bank's CYTO Position: Q2 2020 in Review

Deutsche Bank sold out of Altamira Therapeutics Ltd (CYTO) in Q2 2020, closing a stake of 16 shares — an estimated $5K sold.

Deutsche Bank first reported a position in CYTO in Q1 2019 and held it in 3 quarters. The position peaked at $10K in Q4 2019. 4 funds tracked by Wall St. Rank hold CYTO as of Q2 2020.

Deutsche Bank reported no remaining Altamira Therapeutics Ltd position as of Q2 2020 after selling out during the quarter.
Deutsche Bank sold 16 Altamira Therapeutics Ltd shares in Q2 2020, an estimated $5K.
Deutsche Bank first reported a position in Altamira Therapeutics Ltd in Q1 2019 and held it in 3 quarters.
Deutsche Bank's Altamira Therapeutics Ltd position peaked at $10K in Q4 2019.
4 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q2 2020.

Based on Deutsche Bank's 13F filing for Q2 2020, filed 13 Aug 2020.